Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Linda Benedict

Dermatology Atlanta, GA Medical Doctor

NPI 1730143041 CMS profile 124527

1800 Howell Mill Rd Nw, Suite 680, Atlanta, GA 30318

Open in the dashboard

General payments

$5,317

272 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Linda Benedict of Atlanta, GA is reported in the CMS Open Payments database as having received $5,317 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $48 2
2023 General $1,108 55
2022 General $1,629 76
2021 General $1,094 60
2020 General $417 22
2019 General $1,021 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Linda Benedict
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Linda Benedict were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Linda Benedict Dermatology median Middle half National median
2019 $1,021 $454 $129–$1,240 $163
2020 $417 $235 $81–$756 $114
2021 $1,094 $377 $108–$1,108 $132
2022 $1,629 $514 $143–$1,391 $149
2023 $1,108 $607 $159–$1,674 $160
2024 $48 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $1,212 66 payments
  2. Regeneron Healthcare Solutions, Inc. $454 18 payments
  3. Incyte Corporation $405 18 payments
  4. Novartis Pharmaceuticals Corporation $336 19 payments
  5. Galderma Laboratories, L.P. $300 18 payments
  6. Pfizer Inc. $283 17 payments
  7. Ortho Dermatologics, a division of Bausch Health US, LLC $246 14 payments
  8. Genzyme Corporation $241 9 payments
  9. LEO Pharma Inc. $226 11 payments
  10. Janssen Biotech, Inc. $224 11 payments
  11. Other $1,390 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,317 272 payments
Products named General payments · program years 2019–2024
  1. SKYRIZI $618 36 payments
  2. HUMIRA $459 24 payments
  3. OPZELURA $405 18 payments
  4. DUPIXENT Inflammation And Immunology $366 15 payments
  5. EUCRISA $283 17 payments
  6. RINVOQ $229 12 payments
  7. TALTZ $215 11 payments
  8. DUPIXENT Immunology $198 7 payments
  9. Winlevi $163 7 payments
  10. STELARA $163 9 payments
  11. Other $2,752 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record